TFEB Cancer Research Results
TFEB, Transcription Factor EB: Click to Expand ⟱
| Source: |
| Type: |
TFEB is a member of the MiT/TFE (microphthalmia/transcription factor E) family and plays a crucial role in controlling the transcription of genes related to lysosome function and autophagy.
• Its subcellular localization (cytosolic versus nuclear) is tightly regulated, with nuclear translocation being associated with transcriptional activation of target genes.
TFEB is emerging as an important regulator in cancer biology, and its role as a prognostic marker is under active research. Its expression and activation state may offer insights into tumor behavior, especially regarding autophagy and metabolic adaptation.
Overexpressed in RCC, Pca,
|
Scientific Papers found: Click to Expand⟱
*p‑tau↓, Treatment of cortical cells or primary neurons with fisetin resulted in significant decreases in the levels of phosphorylated tau.
*NRF2↑, Fisetin activated autophagy together with the activation of transcription factor EB (TFEB) and Nrf2 transcriptional factors
*mTORC1↓, fisetin-mediated mammalian target of rapamycin complex 1 (mTORC1) inhibition
*neuroP↑, fisetin showed neurotrophic activity distinct from other flavonoids, and exhibited the most potent, neuroprotective effects8
*memory↑, and promotes memory in wild type mice9
*Inflam↓, fisetin also has a strong anti-inflammatory activity in brain
*memory↑, and its oral administration significantly attenuated the development of learning and memory deficits in an AD mouse model1
*TFEB↑, Fisetin activates TFEB
*mTOR↓, Fisetin inhibits mTOR.
| - |
in-vitro, |
Cerv, |
HeLa |
|
|
|
- |
in-vitro, |
Nor, |
1321N1 |
|
|
|
*ROS↓, SFN may trigger a self-defense cellular mechanism that can effectively mitigate oxidative stress commonly associated with many metabolic and age-related diseases. SFN treatment prevented CCCP-induced ROS increases in WT 1321N1 cells(normal)
*BioAv↑, Tissue concentrations of SFN can reach 3–30 μM upon broccoli consumption
LC3II↑, SFN (15 μM, 3–9 h) treatment markedly increased endogenous LC3-II levels in HeLa cells
LAMP1?, gradual (within hours) increases in the expression of LAMP1 proteins upon SFN (15 μM, 3–9 h) treatment in HeLa cells
TumAuto↑, SFN led to enhanced lysosomal and autophagic function.
TFEB↑, SFN (10–15 μM) treatment for 4 h induced nuclear translocation of endogenous TFEB in HeLa cells
ROS↑, SFN treatment for 2 h resulted in a mild increase of intracellular ROS. ROS mediate some effects of SFN
eff↓, NAC (5 mM), a commonly used membrane-permeable antioxidant compound [7], prevented SFN-induced increases in ROS
Showing Research Papers: 1 to 2 of 2
* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2
Pathway results for Effect on Cancer / Diseased Cells:
Redox & Oxidative Stress(tgid=1) ⓘ
ROS↑, 1,
Autophagy & Lysosomes(tgid=9) ⓘ
LC3II↑, 1, TFEB↑, 1, TumAuto↑, 1,
Migration(tgid=13) ⓘ
LAMP1?, 1,
Drug Metabolism & Resistance(tgid=21) ⓘ
eff↓, 1,
Total Targets: 6
Pathway results for Effect on Normal Cells:
Redox & Oxidative Stress(tgid=1) ⓘ
NRF2↑, 1, ROS↓, 1,
Autophagy & Lysosomes(tgid=9) ⓘ
TFEB↑, 1,
Proliferation, Differentiation & Cell State(tgid=12) ⓘ
mTOR↓, 1, mTORC1↓, 1,
Immune & Inflammatory Signaling(tgid=16) ⓘ
Inflam↓, 1,
Synaptic & Neurotransmission(tgid=18) ⓘ
p‑tau↓, 1,
Drug Metabolism & Resistance(tgid=21) ⓘ
BioAv↑, 1,
Functional Outcomes(tgid=23) ⓘ
memory↑, 2, neuroP↑, 1,
Total Targets: 10
Scientific Paper Hit Count for: TFEB, Transcription Factor EB
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1102 State#:% Dir#:2
wNotes=on sortOrder:rid,rpid
Home Page